American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 507-518 , March 2010

Risks of Kidney Failure Associated With Consumption of Herbal Products Containing Mu Tong or Fangchi: A Population-Based Case-Control Study

  • Ming-Nan Lai, MD

      Affiliations

    • Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taipei, Taiwan
    • ,
  • Jung-Nien Lai, MD, PhD

      Affiliations

    • Division of Gynaecology of Traditional Chinese Medicine, Taipei City Hospital, Taipei, Taiwan
    • ,
  • Pau-Chung Chen, MD, PhD

      Affiliations

    • Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taipei, Taiwan
    • ,
  • Shu-Ching Hsieh, MS, PhD

      Affiliations

    • Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan
    • ,
  • Fu-Chang Hu, MS, ScD

      Affiliations

    • Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Jung-Der Wang, MD, ScD

      Affiliations

    • Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, Taipei, Taiwan
    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationAddress correspondence to Jung-Der Wang, MD, ScD, Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, National Taiwan University, No.17 Xu-Zhou Rd, Taipei City, 100, Taiwan

Received 1 June 2009 ,Accepted 20 October 2009.

References 

  1. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 Annual Data Report: international comparisons. Am J Kidney Dis. 2005;45(1 suppl 1):S217–S224
  2. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49(1):46–55
  3. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant. 2008;23(12):3977–3982
  4. Hsu CC, Hwang SJ, Wen CP, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis. 2006;48(5):727–738
  5. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive interstitial renal fibrosis associated Chinese herbal drug. Am J Kidney Dis. 2000;35(2):313–318
  6. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial fibrosis associated with Chinese herbal medications. Am J Nephrol. 2001;21(6):441–448
  7. Yang HY, Lin JL, Chen KH, et al. Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol. 2006;19(1):111–114
  8. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387–391
  9. Wen CP, Cheng TYD, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462293 adults in Taiwan. Lancet. 2008;371(9631):2173–2182
  10. Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, Wang JD. The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Safety. 2008;17(6):609–619
  11. Committee on Chinese Medicine and Pharmacy, the Department of Health. Regulation of drugs [in Chinese]. http://www.ccmp.gov.tw/public/public.asp?selno=816&relno=816&level=CAccessed January 10, 2008
  12. Government Information Office. Taiwan yearbook 2004, public health: health insurance. http://www.gio.gov.tw/taiwan-website/5-gp/yearbook/2004/P243.htmAccessed December 25, 2009
  13. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology. 2009;14(2):227–234
  14. National Health Research Institutes. National Health Insurance Research database. http://www.nhri.org.tw/nhird/date_01.html#_edn1Accessed January 3, 2009
  15. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  16. Committee on Chinese Medicine and Pharmacy, the Department of Health. Unified formulas. http://www.ccmp.gov.tw/en/information/formula.asp?relno=52&level=CAccessed January 10, 2008
  17. Hsu YH, Tseng HH, Wen KC. Determination of aristolochic acid in Fangchi radix [in Chinese]. In: Annual Report of National Laboratory of Food and Drug. Taiwan ROC: Bureau of Food and Drug Analysis; 1997;p. 136–14215
  18. Tung CF, Ho YL, Tsai HY, Chong YS. Studies on the commonly misused and adulterated Chinese crude drug species in Taiwan [in Chinese]. Chin Med Coll J. 1999;8(1):35–46
  19. Deng JS. Quality Evaluation of Fang-Ji and Analysis of Marker Constituents. [dissertation] In: Taiwan: Institute of Chinese Pharmaceutical Sciences, China Medical University; 2002;p. 75–77
  20. Chuang MS, Hsu YH, Chang HC, Lin JH, Liao CH. Studies on adulteration and misusage of marketed Akebiae caulisn [in Chinese]. In: Annual Report of National Laboratory of Food and Drug. Taiwan ROC: Bureau of Food and Drug Analysis; 2002;p. 104–11920
  21. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age Standardization of Rates: A New WHO Standard. GPE Discussion Paper Series no. 31. Geneva, Switzerland: World Health Organization; 2000;
  22. Taiwan Bureau of Heath Promotion, Department of Health. C2003: Adult and Elderly Health Division [in Chinese]. http://www.bhp.doh.gov.tw/health91/study-2.htmAccessed February 10, 2008
  23. Feest TG, Mistry CD, Grimes DS, Mallick NP. Incidence of advanced chronic renal failure and the need for end-stage renal replacement treatment. BMJ. 1990;301(6757):897–903
  24. Maisonneuve P. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35(1):157–165
  25. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin: renal morbidity and mortality (1968-1979). N Engl J Med. 1983;308(7):357–362
  26. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med. 1989;320(19):1238–1243
  27. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675–1679
  28. Feinstein AR, Heinemann LA, Curhan GC, et al. Relationship between nonphenacetin combined analgesics and nephropathy: a review (Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy). Kidney Int. 2000;58(6):2259–2264
  29. Martena MJ, van der Wielen JCA, van der Laak LFJ, Konings EJM, de Groot HN, Rietjens IMCM. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal Bional Chem. 2007;389(1):263–275
  30. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs [letter]. Lancet. 1994;343(8890):174
  31. Martinez MM, Nortier J, Vereerstraeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol Dial Transplant. 2002;17(3):408–412
  32. Ohno T, Mikami E, Matsumoto H, Kawaguchi N. Identification tests of aristolochic acid in crude drugs by reversed-phase TLC/scanning densitometry. J Health Sci. 2006;52(1):78–81
  33. Jong TT, Lee MR, Hsiao SS, et al. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal. 2003;33(4):831–837
  34. Hsu YH, Lo CF, Chang HC, Lin JH. Studies on adulteration and misusage of Asari radi in the market [in Chinese]. In: Annual Report of National Laboratory of Food and Drug. Taiwan ROC: Bureau of Food and Drug Analysis; 2003;p. 153–16721
  35. Chen XQ, Wang SS. Cardiac arrhythmia induced by excessive xi xin (1 case) [abstract] [in Chinese]. Jiangsu J Tradit Chin Med. 1994;15(1):10
  36. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158–169

 Originally published online as doi:10.1053/j.ajkd.2009.10.055 on February 1, 2010.

PII: S0272-6386(09)01562-5

doi: 10.1053/j.ajkd.2009.10.055

American Journal of Kidney Diseases
Volume 55, Issue 3 , Pages 507-518 , March 2010

Article Tools

* Image Usage & Resolution